Published in PLoS One on April 26, 2012
Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother (2012) 1.18
Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter. Biomed Res Int (2015) 0.78
The concentration of carbon source in the medium affects the quality of virus-like particles of human papillomavirus type 16 produced in Saccharomyces cerevisiae. PLoS One (2014) 0.76
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77
Current understanding of the mechanism of HPV infection. Gynecol Oncol (2010) 1.74
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology (2001) 1.52
Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS (2009) 1.36
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol (2008) 1.35
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol (2009) 1.35
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif (1999) 1.21
Replication and assembly of human papillomaviruses. J Dent Res (2009) 1.20
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18
Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci (2006) 1.15
Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120. J Biol Chem (2001) 1.12
Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol (2005) 1.11
SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood (2005) 1.08
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology (2007) 1.07
Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol (2010) 1.05
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther (2009) 1.02
Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol (2006) 1.02
Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci (2005) 1.00
Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol (2007) 0.99
Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol (2011) 0.96
Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol (2006) 0.93
Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120. J Virol (2010) 0.91
MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity. Hum Immunol (2006) 0.89
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine (2009) 0.89
Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. J Virol Methods (2005) 0.87
Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae. J Biotechnol (2010) 0.87
One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif (2009) 0.87
Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice. Clin Vaccine Immunol (2007) 0.86
Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology (2007) 0.84
Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res (2009) 0.83
Yeast coexpression of human papillomavirus types 6 and 16 capsid proteins. Virology (2002) 0.80
Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J Virol Methods (2006) 0.80
Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif (2008) 0.79
Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae. J Microbiol Biotechnol (2007) 0.77
Predicting genes expressed via -1 and +1 frameshifts. Nucleic Acids Res (2004) 1.18
Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study. World J Surg (2013) 1.08
A comparative study of the effects of whole red ginseng extract and polysaccharide and saponin fractions on influenza A (H1N1) virus infection. Biol Pharm Bull (2013) 0.90
Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae. J Biotechnol (2010) 0.87
One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif (2009) 0.87
Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol Cancer Ther (2006) 0.86
Intake of korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza a virus. J Ginseng Res (2012) 0.85
Current status of laparoscopic liver resection in Korea. J Korean Med Sci (2012) 0.84
Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep (2007) 0.82
Determination of malignant and invasive predictors in branch duct type intraductal papillary mucinous neoplasms of the pancreas: a suggested scoring formula. J Korean Med Sci (2011) 0.81
The glycosylation and in vivo stability of human granulocyte-macrophage colony-stimulating factor produced in rice cells. Biol Pharm Bull (2008) 0.80
Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J Virol Methods (2006) 0.80
The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae. J Microbiol (2012) 0.80
Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Vaccine (2012) 0.80
Studies on the anti-inflammatory effects of Clerodendron trichotomum Thunberg leaves. Arch Pharm Res (2004) 0.80
Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus. Arch Pharm Res (2007) 0.79
A single port laparoscopic surgery robot with high force transmission and a large workspace. Surg Endosc (2014) 0.79
Codon optimization of the human papillomavirus type 58 L1 gene enhances the expression of soluble L1 protein in Saccharomyces cerevisiae. Biotechnol Lett (2012) 0.79
Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea. Ann Surg Oncol (2014) 0.79
Cytotoxic lignans from the stem bark of Magnolia officinalis. J Nat Prod (2007) 0.79
The composition of the carbon source and the time of cell harvest are critical determinants of the final yield of human papillomavirus type 16 L1 protein produced in Saccharomyces cerevisiae. Protein Expr Purif (2011) 0.79
Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles. Protein Expr Purif (2013) 0.79
Simple and convenient chromatography-based methods for purifying the pseudovirus of human papillomavirus type 58. Protein Expr Purif (2010) 0.79
Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif (2008) 0.79
Ameliorating Effect of Dietary Xylitol on Human Respiratory Syncytial Virus (hRSV) Infection. Biol Pharm Bull (2016) 0.78
A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from Saccharomyces cerevisiae. Arch Pharm Res (2010) 0.78
A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice. Int Immunopharmacol (2009) 0.78
Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae. J Microbiol Biotechnol (2007) 0.77
Antibody-based enzyme-linked lectin assay (ABELLA) for the sialylated recombinant human erythropoietin present in culture supernatant. J Pharm Biomed Anal (2008) 0.77
Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. Arch Pharm Res (2009) 0.77
Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions. Arch Pharm Res (2009) 0.76
Anti-inflammatory constituents isolated from Clerodendron trichotomum Tunberg Leaves (CTL) inhibits pro-inflammatory gene expression in LPS-stimulated RAW 264.7 macrophages by suppressing NF-kappaB activation. Arch Pharm Res (2007) 0.75
The effect of dietary intake of the acidic protein fraction of bovine colostrum on influenza A (H1N1) virus infection. J Microbiol (2013) 0.75
Evaluation of viral clearance in the production of HPV-16 L1 virus-like particles purified from insect cell cultures. Biologicals (2006) 0.75
Glycosylation variant analysis of recombinant human tissue plasminogen activator produced in urea-cycle-enzyme-expressing Chinese hamster ovary (CHO) cell line. J Biosci Bioeng (2006) 0.75
Expression and purification of human papillomavirus 18 L1 virus-like particle from saccharomyces cerevisiae. Arch Pharm Res (2008) 0.75
A single serum dilution enzyme-linked immunosorbent assay for determining anti-human papillomavirus (HPV) antibody titres in humans immunised with prophylactic HPV vaccines. J Pharm Biomed Anal (2012) 0.75
Increased sialylation and reduced fucosylation of exfoliated cervical cells are potential markers of carcinogenesis in the cervix. Clin Chem Lab Med (2016) 0.75
Molecular differentiation of Panax species by RAPD analysis. Arch Pharm Res (2003) 0.75
The effect of dietary bovine colostrum on respiratory syncytial virus infection and immune responses following the infection in the mouse. J Microbiol (2015) 0.75
Effect of dietary bovine colostrum on the responses of immune cells to stimulation with bacterial lipopolysaccharide. Arch Pharm Res (2014) 0.75
The glycosylation and pharmacokinetics of CTLA4Ig produced in rice cells. Biol Pharm Bull (2007) 0.75
A comparative study of the adjuvanticity of Hansenula polymorpha, Saccharomyces cerevsiae and Yarrowia lipolytica in oral and nasal immunization with virus capsid antigens. Biotechnol Lett (2013) 0.75